Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7662729 | 0.98 | POLB (0.45) | ERN1TDP1POLBCSNK2A1MEN1 | |
| SCHEMBL275626 | 0.97 | POLB (0.44) | ERN1TDP1POLBCSNK2A1MEN1 | |
| SCHEMBL275979 | 0.88 | CHEK1 (0.42) | ERN1TDP1MEN1KMT2APDE4B | |
| SCHEMBL274642 | 0.88 | ERN1 (0.40) | ERN1TDP1MEN1KMT2AHPGD | |
| SCHEMBL3663943 | 0.84 | TDP1 (0.44) | ERN1TDP1POLBCSNK2A1SLC6A4 | |
| SCHEMBL275938 | 0.82 | CACNB4 (0.41) | ERN1TDP1POLBMEN1KMT2A | |
| SCHEMBL24190659 | 0.81 | TDP1 (0.48) | ERN1TDP1POLBSLC6A4HTR6 | |
| SCHEMBL30396359 | 0.81 | TDP1 (0.48) | ERN1TDP1POLBSLC6A4HTR6 | |
| SCHEMBL18003630 | 0.80 | POLB (0.49) | ERN1TDP1POLBSLC6A4HTR6 | |
| SCHEMBL275350 | 0.80 | FPR2 (0.36) | ERN1POLBMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2014-10-30 | — | — | US | disclosed |
| EP-2766344-A1 | EP1 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013037960-A1 | EP1 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | PTGER1, PTGER2, PTGIR | ERN1 1084/4885TDP1 4377/4885POLB 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.